TSE:REUN Reunion Neuroscience (REUN) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day RangeC$1.42▼C$1.4252-Week Range N/AVolume339 shsAverage Volume12,447 shsMarket CapitalizationC$16.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Reunion Neuroscience alerts: Email Address Ad DTII want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! About Reunion Neuroscience Stock (TSE:REUN)Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.Read More Ad DTII want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! REUN Stock News HeadlinesAugust 26, 2024 | msn.comWhy are so many Roman statues headless?August 5, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc flat on Wednesday (REUN)September 16, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 1, 2023 | finance.yahoo.comReunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of ArrangementJuly 16, 2023 | theglobeandmail.comReunion Neuroscience: Stocks Overvalued by Analyst Consensus on TSX (REUN)July 14, 2023 | finance.yahoo.comReunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of ArrangementJuly 13, 2023 | marketwatch.comReunion Neuroscience Shareholders Agree to $13.1M Sale to MPM BioImpactJuly 13, 2023 | finance.yahoo.comReunion Neuroscience Inc. Shareholders Approve Proposed Plan of ArrangementSeptember 16, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.June 2, 2023 | finance.yahoo.comWhat's Going On With Reunion Neuroscience Stock TodayJune 1, 2023 | msn.comReunion Neuroscience Explodes Higher on Buyout DealJune 1, 2023 | msn.comReunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment FirmJune 1, 2023 | technews.tmcnet.comREUN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reunion Neuroscience Inc. Is Fair to ShareholdersApril 25, 2023 | benzinga.comReunion Neuroscience Enters Compliance Period, Struggles To Remain NASDAQ ListedMarch 27, 2023 | finance.yahoo.comReunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual MeetingMarch 3, 2023 | foxnews.com‘Jeopardy!” contestant tells Mayim Bialik that she was his childhood crush: ‘You haven’t aged a day!’February 22, 2023 | msn.comThe first-ever ‘Jeopardy!’ High School Reunion is packed with New EnglandersFebruary 14, 2023 | markets.businessinsider.comEF Hutton Reaffirms Their Buy Rating on Reunion Neuroscience (REUN)See More Headlines Receive REUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryHealthcare Current SymbolTSE:REUN CUSIPN/A CIKN/A Webwww.fieldtriphealth.com Phone888-519-6016FaxN/AEmployees190Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-38,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.35% Return on Assets-26.50% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick RatioN/A Sales & Book Value Annual SalesC$4.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.82 per share Price / BookN/AMiscellaneous Outstanding Shares11,720,000Free FloatN/AMarket CapC$16.64 million OptionableNot Optionable Beta4.20 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Hannan Fleiman (Age 42)Co-Founder & Non-Independent Director Comp: $282.64kDr. Nathan Bryson B.Sc. (Age 59)Ph.D., Chief Science Officer Comp: $411.37kMr. Gregory T. Mayes Esq. (Age 54)J.D., Pres, CEO & Director Mr. Edward F. Smith CPA (Age 52)Chief Financial Officer Mr. Curtis WeberGen. CounselMr. Stephan CoteHead of QualityDr. Robert Alexander M.D.Chief Medical Officer & Sr. AdvisorMore ExecutivesKey CompetitorsMidland ExplorationCVE:MDTrilogy International PartnersTSE:TRLBreaking DataCVE:BKDFocus GraphiteCVE:FMS217932 (NHC.TO)TSE:NHCView All Competitors REUN Stock Analysis - Frequently Asked Questions How do I buy shares of Reunion Neuroscience? Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:REUN) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reunion Neuroscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reunion Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.